Phycocyanin Ameliorates Colitis-Associated Colorectal Cancer by Regulating the Gut Microbiota and the IL-17 Signaling Pathway

Mar Drugs. 2022 Apr 9;20(4):260. doi: 10.3390/md20040260.

Abstract

Phycocyanin (PC) is a pigment-protein complex. It has been reported that PC exerts anti-colorectal cancer activities, although the underlying mechanism has not been fully elucidated. In the present study, azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced mice were orally administrated with PC, followed by microbiota and transcriptomic analyses to investigate the effects of PC on colitis-associated cancer (CAC). Our results indicated that PC ameliorated AOM/DSS induced inflammation. PC treatment significantly reduced the number of colorectal tumors and inhibited proliferation of epithelial cell in CAC mice. Moreover, PC reduced the relative abundance of Firmicutes, Deferribacteres, Proteobacteria and Epsilonbacteraeota at phylum level. Transcriptomic analysis showed that the expression of genes involved in the intestinal barrier were altered upon PC administration, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed the IL-17 signaling pathway was affected by PC treatment. The study demonstrated the protective therapeutic action of PC on CAC.

Keywords: IL-17 pathway; colorectal cancer; microbiota; phycocyanin; transcriptome.

MeSH terms

  • Animals
  • Azoxymethane / toxicity
  • Colitis* / chemically induced
  • Colitis* / complications
  • Colitis* / drug therapy
  • Colitis-Associated Neoplasms*
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / metabolism
  • Dextran Sulfate / toxicity
  • Disease Models, Animal
  • Gastrointestinal Microbiome*
  • Interleukin-17
  • Mice
  • Mice, Inbred C57BL
  • Phycocyanin / metabolism
  • Phycocyanin / pharmacology
  • Phycocyanin / therapeutic use
  • Signal Transduction

Substances

  • Interleukin-17
  • Phycocyanin
  • Dextran Sulfate
  • Azoxymethane